118 related articles for article (PubMed ID: 36178306)
21. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
22. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
24. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.
Awan MJ; Nedzi L; Wang D; Tumati V; Sumer B; Xie XJ; Smith I; Truelson J; Hughes R; Myers LL; Lavertu P; Wong S; Yao M
Ann Oncol; 2018 Apr; 29(4):998-1003. PubMed ID: 29346519
[TBL] [Abstract][Full Text] [Related]
25. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Wang K; Dong J; He S; Wang X; Jiang C; Hu P; Guo J; Cai X; Wang X
BMC Cancer; 2019 May; 19(1):482. PubMed ID: 31117967
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
27. Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.
Morse RT; Ganju RG; TenNapel MJ; Neupane P; Kakarala K; Shnayder Y; Chen AM; Lominska CE
Head Neck; 2019 Aug; 41(8):2492-2499. PubMed ID: 30856297
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
[TBL] [Abstract][Full Text] [Related]
29. Weekly Chemotherapy of 5-Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
Chen B; Li Q; Li Q; Qiu B; Xi M; Liu M; Hu Y; Zhu Y
Oncologist; 2020 Apr; 25(4):308-e625. PubMed ID: 31880371
[TBL] [Abstract][Full Text] [Related]
30. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
33. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
Schaeffers AWMA; Devriese LA; van Gils CH; Dankbaar JW; Voortman J; de Boer JP; Slingerland M; Hendriks MP; Smid EJ; Frederix GWJ; de Bree R
PLoS One; 2023; 18(11):e0294147. PubMed ID: 38011186
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Gulati S; Desai J; Palackdharry SM; Morris JC; Zhu Z; Jandarov R; Riaz MK; Takiar V; Mierzwa M; Gutkind JS; Molinolo A; Desai PB; Sadraei NH; Wise-Draper TM
Cancer; 2020 Jan; 126(2):354-362. PubMed ID: 31626727
[TBL] [Abstract][Full Text] [Related]
35. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
36. Treatment Outcomes of Head and Neck Cancer Patients in the Elderly Receiving Different Chemoradiation Combinations: A Single-Center Experience.
Karivedu V; Bonomi M; Issa M; Blakaj A; Klamer BG; Pan X; Old M; Bhateja P; Kang S; Seim N; Ozer E; Agrawal A; Mitchell D; Gamez ME; Grecula J; Jhawar SR; Baliga S; Carrau RL; Rocco J; Blakaj D
Oncol Res Treat; 2021; 44(10):521-529. PubMed ID: 34515190
[TBL] [Abstract][Full Text] [Related]
37. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
[TBL] [Abstract][Full Text] [Related]
39. Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin.
Corry J; Bressel M; Fua T; Herschtal A; Solomon B; Porceddu SV; Wratten C; Rischin D
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):948-954. PubMed ID: 28483336
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Vanderveken OM; Szturz P; Specenier P; Merlano MC; Benasso M; Van Gestel D; Wouters K; Van Laer C; Van den Weyngaert D; Peeters M; Vermorken J
Oncologist; 2016 Jan; 21(1):59-71. PubMed ID: 26712958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
